{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:42:14Z","timestamp":1792024934494,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12916-4","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:13:13Z","timestamp":1772075593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic diversity and drug resistance mutations of HIV-1 in Ghana: a systematic review of two decades"],"prefix":"10.1186","volume":"26","author":[{"given":"Pious","family":"Appiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mildred","family":"Adusei-Poku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billal Musah","family":"Obeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Osei-Yeboah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspah","family":"Gbassana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Agyemang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennox","family":"Mac-Ankrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Jamfaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makafui","family":"Seshie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Kwame","family":"Sraku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ankamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwabena Obeng","family":"Duedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena William Coleman","family":"Sagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"12916_CR1","unstructured":"UNAIDS, \u201cFACT SHEET 2024: Global HIV statistics.\u201d UNAIDS, 2024. Accessed: Oct. 20, 2024. [Online]. Available: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf."},{"key":"12916_CR2","doi-asserted-by":"publisher","unstructured":"Addo NA, Yawson AE, Addo AS, Dornoo BT, Seneadza HNA. A review of national programme data on the HIV epidemic in Ghana: 2005\u20132010. GCPS. 2022 Jul;3(2):73\u201381. https:\/\/doi.org\/10.60014\/pmjg.v3i2.65.","DOI":"10.60014\/pmjg.v3i2.65"},{"key":"12916_CR3","unstructured":"Neequaye J, et al. Sexual habits and social factors in local Ghanaian prostitutes which could affect the spread of human immune deficiency virus (HIV), Ghana Med J. 1987;21:12\u201315. Available: https:\/\/journal.gcps.edu.gh\/index.php\/pmjg\/article\/view\/65\/57."},{"key":"12916_CR4","unstructured":"ACP and GHS, \u201cCONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA: Test, Treat & Track.\u201d National AIDS\/STI Control Programme, 2022. [Online]. Available: https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/Consolidated-Guidelines-For-Hiv-Care-In-Ghana.pdf."},{"key":"12916_CR5","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","author":"WHO","year":"2021","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2021.","edition":"2"},{"key":"12916_CR6","doi-asserted-by":"publisher","unstructured":"Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006841. https:\/\/doi.org\/10.1101\/cshperspect.a006841.","DOI":"10.1101\/cshperspect.a006841"},{"key":"12916_CR7","doi-asserted-by":"publisher","unstructured":"Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019 May;14(3):153\u2013160. https:\/\/doi.org\/10.1097\/COH.0000000000000534.","DOI":"10.1097\/COH.0000000000000534"},{"key":"12916_CR8","doi-asserted-by":"publisher","unstructured":"Appah A, et al. Molecular Epidemiology of HIV-1 in Ghana: subtype distribution, drug resistance and coreceptor usage. Viruses. 2022 Dec;15(1):128. https:\/\/doi.org\/10.3390\/v15010128.","DOI":"10.3390\/v15010128"},{"key":"12916_CR9","doi-asserted-by":"publisher","unstructured":"Fischetti L, Opare-Sem O, Candotti D, Sarkodie F, Lee H, Allain JP. Molecular epidemiology of HIV in Ghana: dominance of CRF02_AG. J Med Virol. 2004 Jun;73(2):158\u2013166. https:\/\/doi.org\/10.1002\/jmv.20070.","DOI":"10.1002\/jmv.20070"},{"key":"12916_CR10","doi-asserted-by":"publisher","unstructured":"Konou AA, et al. Genetic diversity and transmission networks of HIV-1 strains among men having sex with men (MSM) in Lom\u00e9, Togo. Infect Genet Evol. 2016 Dec;46:279\u201385. https:\/\/doi.org\/10.1016\/j.meegid.2016.05.030.","DOI":"10.1016\/j.meegid.2016.05.030"},{"key":"12916_CR11","doi-asserted-by":"publisher","unstructured":"Tebit DM, Sangar\u00e9 L, Tiba F, Saydou Y, Yameogo S, Ouedraogo-Traore R, et al. Analysis of the diversity of the HIV-1 pol gene and drug resistance\u2013associated changes among drug-na\u00efve patients in Burkina Faso. J Med Virol. 2009 Oct;81(10):1691\u20131701. https:\/\/doi.org\/10.1002\/jmv.21600.","DOI":"10.1002\/jmv.21600"},{"key":"12916_CR12","doi-asserted-by":"publisher","unstructured":"Soubeiga ST, et al. Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso. J Public Health Afr. 2018 Jul.https:\/\/doi.org\/10.4081\/jphia.2018.767.","DOI":"10.4081\/jphia.2018.767"},{"key":"12916_CR13","doi-asserted-by":"publisher","unstructured":"Nazziwa J, et al. Characterisation of HIV-1 Molecular epidemiology in Nigeria: origin, diversity, demography and geographic spread. Sci Rep. 2020 Feb;10(1):3468. https:\/\/doi.org\/10.1038\/s41598-020-59944-x.","DOI":"10.1038\/s41598-020-59944-x"},{"key":"12916_CR14","doi-asserted-by":"publisher","unstructured":"Abongwa LE, Nyamache AK, Torimiro JN, Okemo P, Charles F. Human immunodeficiency virus type 1 ((HIV-1) subtypes in the northwest region, Cameroon. Virol J. 2019 Dec;16(1):103. https:\/\/doi.org\/10.1186\/s12985-019-1209-6.","DOI":"10.1186\/s12985-019-1209-6"},{"key":"12916_CR15","doi-asserted-by":"publisher","unstructured":"Amer AN, Gaballah A, Emad R, Ghazal A, Attia N. Molecular epidemiology of HIV-1 virus in Egypt: a major change in the circulating subtypes. Curr HIV Res. 2021 Sep;19(5):448\u2013456. https:\/\/doi.org\/10.2174\/1570162X19666210805091742.","DOI":"10.2174\/1570162X19666210805091742"},{"key":"12916_CR16","doi-asserted-by":"publisher","unstructured":"Mbonye U, Karn J. The cell biology of HIV-1 latency and rebound. Retrovirology. 2024 Apr;21(1). https:\/\/doi.org\/10.1186\/s12977-024-00639-w.","DOI":"10.1186\/s12977-024-00639-w"},{"key":"12916_CR17","unstructured":"WHO. HIV drug resistance. World Health Organization, 2024. Accessed: Oct. 20, 2024. [Online]. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance."},{"key":"12916_CR18","doi-asserted-by":"publisher","unstructured":"Brandful JAM, et al. Phenotypic characterization of HIV type 1 isolates from Ghana. AIDS Res Hum Retroviruses. 2007 Jan;23(1):144\u201352. https:\/\/doi.org\/10.1089\/aid.2007.23.144.","DOI":"10.1089\/aid.2007.23.144"},{"key":"12916_CR19","doi-asserted-by":"publisher","unstructured":"Sagoe KWC, Djorbeng-Danquah E, Brandful JA, Bonney EY, Ampofo WK, Ofori-Adjei D, et al. Variability of the human immunodeficiency virus type 1 polymerase gene from treatment-na\u00efve patients in Accra, Ghana. J Clin Virol. 2007 Oct;40(2):163\u2013167. https:\/\/doi.org\/10.1016\/j.jcv.2007.07.016.","DOI":"10.1016\/j.jcv.2007.07.016"},{"key":"12916_CR20","doi-asserted-by":"publisher","unstructured":"Delgado E, Ampofo WK, Sierra M, Torpey K, P\u00e9rez-Alvarez L, Bonney EY, et al. High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study. J Acquir Immune Defic Syndr. 2008 Aug;48(5):599\u2013606. https:\/\/doi.org\/10.1097\/QAI.0b013e3181806c0e.","DOI":"10.1097\/QAI.0b013e3181806c0e"},{"key":"12916_CR21","doi-asserted-by":"publisher","unstructured":"Brandful JAM, Candotti D, Allain JP. Genotypic diversity and mutation profile of HIV-1 strains in antiretroviral treatment (ART)-na\u00efve Ghanaian patients and implications for antiretroviral treatment (ART). J AIDS HIV Res. 2012 Jul;4(7):187\u2013197. https:\/\/doi.org\/10.5897\/JAHR12.008.","DOI":"10.5897\/JAHR12.008"},{"key":"12916_CR22","doi-asserted-by":"publisher","unstructured":"Nii-Trebi NI, et al. HIV-1 Drug-resistance surveillance among treatment-experienced and -na\u00efve patients after the implementation of antiretroviral therapy in Ghana. PLoS ONE. 2013 Aug;8(8):e71972. https:\/\/doi.org\/10.1371\/journal.pone.0071972.","DOI":"10.1371\/journal.pone.0071972"},{"key":"12916_CR23","unstructured":"Bonney EY, Addo NA, Ntim NA, Brandful JA, Ampofo WK, Ofori-Adjei D, et al. Low level of transmitted HIV drug resistance at two HIV care centres in Ghana: a threshold survey. Ghana Med J. 2013 Jun;47(2):82\u201386."},{"key":"12916_CR24","doi-asserted-by":"publisher","unstructured":"Nii-Trebi NI, Obeng BM, Ampofo WK, Brandful JA. Epidemiologic dominance of HIV-1 subtype CRF02_AG in Ghana: preliminary virological evidence of increasing association with new infections. Int J Virol AIDS. 2016 Apr;3:022\u2013028. https:\/\/doi.org\/10.19070\/2330-0027-160004.","DOI":"10.19070\/2330-0027-160004"},{"key":"12916_CR25","doi-asserted-by":"publisher","unstructured":"Martin-Odoom A, Adiku T, Delgado E, Lartey M, Ampofo WK. Occurrence of transmitted HIV-1 drug resistance among drug-na\u00efve pregnant women in selected HIV-care centres in Ghana. Ghana Med J. 2017 Apr;51(1):20. https:\/\/doi.org\/10.4314\/gmj.v51i1.4.","DOI":"10.4314\/gmj.v51i1.4"},{"key":"12916_CR26","doi-asserted-by":"publisher","unstructured":"Martin-Odoom A, et al. Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana. Virol J. 2018 Dec;15(1):143. https:\/\/doi.org\/10.1186\/s12985-018-1051-2.","DOI":"10.1186\/s12985-018-1051-2"},{"key":"12916_CR27","doi-asserted-by":"publisher","unstructured":"Deletsu SD, Maina EK, Quaye O, Ampofo WK, Awandare GA, Bonney EY. High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy. Med (Baltim). 2020 Feb;99(7):e18777. https:\/\/doi.org\/10.1097\/MD.0000000000018777.","DOI":"10.1097\/MD.0000000000018777"},{"key":"12916_CR28","doi-asserted-by":"publisher","unstructured":"Obeng BM, et al. Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana. Virol J. 2020 Dec;17(1):114. https:\/\/doi.org\/10.1186\/s12985-020-01386-y.","DOI":"10.1186\/s12985-020-01386-y"},{"key":"12916_CR29","unstructured":"Quansah DNK. Transmitted drug resistance and co-receptor tropism of circulating HIV-1 subtypes in art-Na\u00c3\u00afve HIV patients in Ghana, University of Ghana, Ugspace, 2021. [Online]. Available: https:\/\/ugspace.ug.edu.gh\/browse\/author?value=Quansah,%2520D.N.K.%26bbm.return=1."},{"key":"12916_CR30","doi-asserted-by":"publisher","unstructured":"Parbie PK, et al. High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; a 2017 study. Front Microbiol. 2022 Aug;13:973771. https:\/\/doi.org\/10.3389\/fmicb.2022.973771.","DOI":"10.3389\/fmicb.2022.973771"},{"key":"12916_CR31","doi-asserted-by":"publisher","unstructured":"Appiah P, Gbassana G, Adusei-Poku M, Obeng BM, Duedu KO, Sagoe KWC. Genetic landscape for majority and minority HIV-1 drug resistance mutations in antiretroviral therapy naive patients in Accra, Ghana. Heliyon. 2024 Jun;10(12):e33180. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33180.","DOI":"10.1016\/j.heliyon.2024.e33180"},{"key":"12916_CR32","doi-asserted-by":"publisher","unstructured":"Seshie M, et al. Resistance to protease inhibitors among persons living with HIV in Ghana: a case for viral load and drug resistance monitoring. Virol J. 2024 Jul;21(1):159. https:\/\/doi.org\/10.1186\/s12985-024-02354-6.","DOI":"10.1186\/s12985-024-02354-6"},{"key":"12916_CR33","doi-asserted-by":"publisher","unstructured":"Nii-Trebi NI, Obeng BM, Ampofo WK, Brandful JA, Bonney EY, Sagoe KWC, et al. Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana. J Med Microbiol. 2017 Nov;66(11):1663\u20131672. https:\/\/doi.org\/10.1099\/jmm.0.000621.","DOI":"10.1099\/jmm.0.000621"},{"key":"12916_CR34","doi-asserted-by":"publisher","unstructured":"Giovanetti M, Ciccozzi M, Parolin C, Borsetti A. Molecular epidemiology of HIV-1 in African countries: a comprehensive overview. Pathogens. 2020 Dec;9(12):1072. https:\/\/doi.org\/10.3390\/pathogens9121072.","DOI":"10.3390\/pathogens9121072"},{"key":"12916_CR35","doi-asserted-by":"publisher","unstructured":"Foka FET, Mufhandu HT. Current ARTs, virologic failure, and implications for AIDS management: a systematic review. Viruses. 2023 Aug;15(8):1732. https:\/\/doi.org\/10.3390\/v15081732.","DOI":"10.3390\/v15081732"},{"key":"12916_CR36","doi-asserted-by":"publisher","unstructured":"Bulla I, Ferretti L, Gianella S, Meyerhans A. HIV classification using the coalescent theory. Bioinformatics. 2010 Jun;26(11):1409\u20131415. https:\/\/doi.org\/10.1093\/bioinformatics\/btq159.","DOI":"10.1093\/bioinformatics\/btq159"},{"key":"12916_CR37","doi-asserted-by":"publisher","unstructured":"Yebra G, et al. A high HIV-1 strain variability in London, UK, revealed by full-genome analysis: results from the ICONIC project. PLoS ONE. 2018 Feb;13(2):e0192081. https:\/\/doi.org\/10.1371\/journal.pone.0192081.","DOI":"10.1371\/journal.pone.0192081"},{"key":"12916_CR38","doi-asserted-by":"publisher","unstructured":"Kline RL, Saduvala N, Zhang T, Oster AM. Diversity and characterization of HIV-1 subtypes in the United States, 2008\u20132016. Ann Epidemiol. 2019 May;33:84\u20138. https:\/\/doi.org\/10.1016\/j.annepidem.2019.02.010.","DOI":"10.1016\/j.annepidem.2019.02.010"},{"key":"12916_CR39","doi-asserted-by":"publisher","unstructured":"Fiebig U, et al. Transmitted drug resistance and subtype patterns of viruses from reported new HIV diagnoses in Germany, 2017\u20132020. BMC Infect Dis. 2023 Oct;23(1):673. https:\/\/doi.org\/10.1186\/s12879-023-08649-3.","DOI":"10.1186\/s12879-023-08649-3"},{"key":"12916_CR40","doi-asserted-by":"publisher","unstructured":"Akouamba BS, Ndong-Atome GR, Boumba LA, Mpoudi-Ngole E, Leroy EM. HIV-1 genetic diversity in antenatal cohort, Canada. Emerg Infect Dis. 2005 Aug;11(8):1230\u20131234. https:\/\/doi.org\/10.3201\/eid1108.040877.","DOI":"10.3201\/eid1108.040877"},{"key":"12916_CR41","doi-asserted-by":"publisher","unstructured":"Pai NP, Karellis A, Kim J, Peter T. Modern diagnostic technologies for HIV. Lancet HIV. 2020 Aug;7(8):e574\u201381. https:\/\/doi.org\/10.1016\/S2352-3018(20)30190-9.","DOI":"10.1016\/S2352-3018(20)30190-9"},{"key":"12916_CR42","doi-asserted-by":"publisher","unstructured":"Stirrup O, et al. Continuation of emtricitabine\/lamivudine within combination antiretroviral therapy following detection of the M184V\/I HIV-1 resistance mutation. HIV Med. 2020 May;21(5):309\u201321. https:\/\/doi.org\/10.1111\/hiv.12829.","DOI":"10.1111\/hiv.12829"},{"key":"12916_CR43","doi-asserted-by":"publisher","unstructured":"Matthews G, et al. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b\/4 trial. Lancet HIV. 2024 Jul;11(7):e436\u201348. https:\/\/doi.org\/10.1016\/S2352-3018(24)00089-4.","DOI":"10.1016\/S2352-3018(24)00089-4"},{"key":"12916_CR44","doi-asserted-by":"publisher","unstructured":"Siddiqui D, et al. Genetic and antiretroviral drug resistance mutations analysis of reverse transcriptase and protease gene from Pakistani people living with HIV-1. PLoS ONE. 2023 Aug;18(8):e0290425. https:\/\/doi.org\/10.1371\/journal.pone.0290425.","DOI":"10.1371\/journal.pone.0290425"},{"key":"12916_CR45","doi-asserted-by":"publisher","unstructured":"Boyer PL, Das K, Arnold E, Hughes SH. Analysis of the zidovudine resistance mutations T215Y, M41L, and L210W in HIV-1 reverse transcriptase. Antimicrob Agents Chemother. 2015 Dec;59(12):7184\u20137196. https:\/\/doi.org\/10.1128\/AAC.05069-14.","DOI":"10.1128\/AAC.05069-14"},{"key":"12916_CR46","doi-asserted-by":"publisher","unstructured":"Rhee S-Y, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010 Oct;54(10):4253\u20134261. https:\/\/doi.org\/10.1128\/AAC.00574-10.","DOI":"10.1128\/AAC.00574-10"},{"key":"12916_CR47","doi-asserted-by":"publisher","unstructured":"Chen G-J, Liu X-L, Zhang L, Li Y, Wang J, Zhou Y, et al. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. Int J Antimicrob Agents. 2019 Jul;54(1):35\u201342. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.03.016.","DOI":"10.1016\/j.ijantimicag.2019.03.016"},{"key":"12916_CR48","doi-asserted-by":"publisher","unstructured":"Ndashimye E, Arts EJ. Dolutegravir response in antiretroviral therapy na\u00efve and experienced patients with M184V\/I: Impact in low-and middle-income settings. Int J Infect Dis. 2021 Apr;105:298\u2013303. https:\/\/doi.org\/10.1016\/j.ijid.2021.03.018.","DOI":"10.1016\/j.ijid.2021.03.018"},{"key":"12916_CR49","unstructured":"World Health Organization. HIV drug resistance: brief report 2024, World Health Organization, Geneva, 2024. Accessed: Nov. 18, 2024. [Online]. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/376039\/9789240086319-eng.pdf."},{"key":"12916_CR50","doi-asserted-by":"publisher","unstructured":"Mbuagbaw L, et al. The impact of routine HIV drug resistance testing in Ontario: a controlled interrupted time series study. PLoS ONE. 2021 Apr;16(4):e0246766. https:\/\/doi.org\/10.1371\/journal.pone.0246766.","DOI":"10.1371\/journal.pone.0246766"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12916-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12916-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12916-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:55:46Z","timestamp":1774968946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12916-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12916"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12916-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6666479\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"700"}}